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The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of
etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I
study: the maximum tolerated doses were epirubicin (EpiDX) 90mgm
 2 and paclitaxel (P) 175mgm
 2 with febrile neutropenia as
dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75mgm
 2, P 175mgm
 2,
etoposide (E) 100mgm
 2 intravenous (fixed dose) days 1–3 with courses repeated every 21 days. The prophylactic use of colony-
stimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50–70),
median Eastern Cooperative Oncology Group performance status 0 (0–2); nine patients had visceral disease and 17 had more than
two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1–6) per patients. Main toxicity (NCI-CTC)
was myelosuppression: neutropenia grades 3 and 4 in 16 and 35% of the courses, respectively. Seven episodes of febrile neutropenia
were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19
evaluable patients achieved a complete response (37%), nine patients (47.3%) a partial response with an overall response rate of
84.2% ((95% confidence interval¼60.4–96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/
etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the
haematological profile.
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Small-cell lung cancer (SCLC) accounts for about 20% of primary
lung cancers and approximately 60% of SCLC patients have
extensive disease (ED) at diagnosis (Coleman et al, 1993). In this
disease, combination regimens are clearly superior to single-agent
ones and they represent the standard of care for patients with good
performance status (PS). However, despite the initial high
sensitivity to treatment, in most cases the disease will ultimately
relapse: this clinical behaviour stresses the need to introduce new
agents and/or new combinations in the management of this poor
prognosis population of patients.
Anthracyclines are highly active against SCLC and they are
included in some of the most widely used combination regimens
such as cyclophosphamide, doxorubicin, vincristine (CAV) and
cyclophosphamide, doxorubicin, etoposide (CDE). Cisplatin/
etoposide (PE) is the reference regimen for the treatment of SCLC
in the United States, while CDE represented one of the reference
regimens in European countries.
So far, intravenous etoposide has been the cornerstone of SCLC
chemotherapy and its activity is clearly schedule dependent. Slevin
et al compared a 1-day intravenous (i.v.) injection of etoposide
(500mgm
 2) to the same dose fractionated over 5 days, every 3
weeks; response rates and survival significantly favoured the 5-day
schedule (Slevin et al, 1989). Activity, efficacy and safety of
prolonged oral etoposide have also been evaluated in SCLC: two
randomised phase III trials compared single-agent oral etoposide
to conventional polichemotherapy in elderly or frail (WHO PS
X2) patients: the results of these studies cast serious doubts on the
role of oral etoposide in this histology (Medical Research Council
Lung Cancer Working Party, 1996; Souhami et al, 1997).
Among the last generation drugs tested in this disease, paclitaxel
was very promising. This drug showed encouraging single-agent
activity as second-line treatment: in patients with ED pretreated
with CDE as first-line combination, single-agent paclitaxel showed
an overall response rate of 29%, which is at the upper level of
activity for any single agent in this setting (Smit et al, 1998). An
interesting activity was also observed in untreated patients; in the
Eastern Cooperative Oncology Group (ECOG) phase II study a 34%
remission rate and a 43-week median survival were observed
(Ettinger et al, 1995); the North Central Cancer Treatment Group
(NCCTG) also reported a 53% response rate in 43 untreated
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spatients (Kirschling et al, 1999). These phase II studies, evaluating
the activity of paclitaxel in ED–SCLC, provided the basis for
inclusion of this drug in polichemotherapy regimens.
On these grounds we performed a phase I/II study to evaluate
the maximum tolerated dose (MTD) of paclitaxel and epirubicin in
combination with a fixed dose of i.v. etoposide as first-line therapy
in ED–SCLC, and to evaluate the toxicity and activity of the triplet,
particularly in terms of complete response.
PATIENTS AND METHODS
Eligibility criteria
The phase I–II study was carried out in chemotherapy-naı ¨ve
patients with histologically proven ED–SCLC, ECOG PS p2 and
aged 70 years or younger. Adequate pretreatment haematological
(WBC count p4000ml
 1, haemoglobin X10gdl
 1, platelet count
X100000ml
 1), hepatic (bilirubin at the normal level) and renal
(creatinine at the normal level) functions were required. Left
ventricular ejection fraction (LVEF) 450% at bidimensional
ultrasonography or MUGA scan was mandatory. Patients with
brain metastases were eligible. Patients were excluded if they had a
positive history of any other type of cancer, with the exception of
radically resected in situ cervical cancer and nonmelanoma skin
cancer, congestive heart failure or other serious medical or
psychiatric illnesses. Written informed consent was obtained from
each patient according to local institution policies. The protocol
was approved by the ethical committees of participating institu-
tions and was conducted according to Good Clinical Practice
guidelines and the Helsinki declaration of the World Medical
Association. The study was supported by Bristol-Myers Italy.
Staging and follow-up procedures
Pretreatment evaluation was performed within 4 weeks before the
beginning of treatment and consisted of: clinical history and
physical examination, complete blood cell counts with differential
and biochemistry, bronchoscopy, chest X-ray, computed tomo-
graphy scan of the chest and abdomen. Other types of organ-
specific scanning were optional but recommended in cases of
symptoms or biochemical abnormalities. During the study,
patients underwent clinical examination and routine biochemistry
before day 1 of each course, while blood cell count was performed
weekly.
Restaging was planned every three courses of chemotherapy: all
target lesions were reassessed with the same method used on study
entry according to WHO criteria (Miller et al, 1981). Patients were
considered evaluable for response if they had received at least
three courses of chemotherapy. All responses were centrally
reviewed and had to be confirmed 28 days or more after the
initial documentation of response.
Toxicities were assessed using the National Cancer Institute
common toxicity criteria, version 2.0 (NCI-CTC) (National Cancer
Institute, 1999) and reported as the worst toxicity observed per
course at any time in the trial.
Treatment plan
Patients entered the phase I part of this study in triplets. Starting
doses were paclitaxel 155mgm
 2 (as a 3-h infusion) on Day 1,
epirubicin 60mgm
 2 (as a slow bolus injection immediately before
paclitaxel) on day 1, etoposide 100mgm
 2 i.v. (1-h infusion
immediately after Paclitaxel) on days 1–3. Premedication for
paclitaxel consisted of 20mg desamethasone by i.v. infusion
30min before treatment; orphenadrine 40mg i.m. plus i.v.
cimetidine 300mg 1h before the start of treatment. The doses of
epirubicin and paclitaxel were escalated in consecutive triplets of
patients until dose-limiting toxicity (Table 1). No intrapatient
escalation was allowed. Chemotherapy was administered on an
outpatient basis every 3 weeks for a maximum of six courses.
Dose-limiting toxicities (DLT) were defined as the occurrence of
one of the following: absolute neutrophil count (ANC) p500ml
 1
lasting more than 7 days or ANCp100ml
 1 for 3 days (72h);
febrile neutropenia; any grade X3 (NCI-CTC) nonhaematological
toxicity except for alopecia. When a DLT was observed in one out
of three patients, three more patients were added at the same dose
level. If an additional patient experienced a DLT, no further dose
escalation was allowed and that dose level was considered as the
MTD. The dose level immediately below MTD was the recom-
mended dose for the phase II study.
In the case of grade 4 neutropenia ciprofloxacin 500mg were
administered orally twice a day and fluconazole 100mg daily until
ANC41000ml. The prophylactic use of colony-stimulating factors
(CSFs) was not allowed but suggested in case of febrile
neutropenia. Patients were admitted to the hospital when febrile
neutropenia lasted more than 72h despite the use of adequate
orally administered antibiotics, antimicotics and CSFs.
Statistical analysis
Having the complete response rate as primary end point, Simon’s
optimal two-stage design for phase II trials was used to calculate
the sample size: with an a error of 0.05 and a b error of 0.10, P0
(clinically uninteresting true complete response rate) and P1
(sufficiently promising true complete response rate) were set at 10
and 30%, respectively. In the first step, 18 patients had to be
included: if p2 complete responses were obtained, accrual was
stopped, otherwise 18 more patients had to be registered. Drug
combination was considered of interest if X7 complete responses
were observed out of 36 evaluable patients. Time to progression
(TTP) was calculated from the date of registration to the date of
clinical and/or radiological evidence of progression or death,
whichever occurred first. Survival was calculated from registration
to death or last follow-up. Survival and TTP were estimated using
the Kaplan–Meier method (Kaplan and Meier, 1993). Data were
analysed using SPSS/PCþ11.5 statistical software.
RESULTS
A total of 33 patients entered the phase I/II trial. Accrual into this
study was stopped as soon as the number of complete responses
required by the statistical design was achieved. Characteristics of
patients were as follows: median age 62 years (range 50–70),
median ECOG PS 0 (range 0–2); the majority of patients had 2 or
more metastatic sites. Demographics are summarized in Table 2.
Phase I study
Thirteen patients were registered: 18 courses were administered at
dose level A (three patients), 18 at dose level B (three patients) and
32 at level C (seven patients); median number of courses
administered per patient 6 (range 1–6). The major toxicity
associated with this regimen was myelosuppression: a grade 4
neutropenia was observed in 11% of the courses in group B and in
47% of the courses in group C; no grade 4 neutropenia was
Table 1 Study design of phase I
Dose level EpiDx P E No. pts
A 60 155 100 3
B 75 175 100 3
C 90 175 100 7
Epirubicin (Epidx); paclitaxel (P); etoposide (E).
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sobserved in group A. No grade 4 thrombocytopenia or anaemia
were observed. The MTD was found at dose level C (EpiDX,
90mgm
 2; P, 175mgm
 2) since two patients experienced febrile
neutropenia (no hospital admission was required). Therefore, the
recommended doses of the two drugs to be used in the phase II
study were those of level B (EpiDx, 75mgm
 2; P, 175mgm
 2).
Nonhaematological toxicities were mild. Baseline median LVEF
was 63.3% (range 57–70%) and no significant modification was
observed after the sixth course of treatment in the whole patients’
population.
Even if activity was not the end point of the phase I part of the
study, considering the fact that all patients enrolled were
chemotherapy naı ¨ve, responses were assessed, with the same
criteria of phase II, every three courses of treatment. Twelve out of
13 patients were evaluable (one patient in group C was lost to
follow-up after the first course of therapy). Six patients (50%)
showed a complete response (two patients from group B and four
patients from group C) and six patients showed a partial response;
the best response was obtained after three courses of treatment.
Phase II study
A total of 100 courses were administered with a median of 5 per
patient (range 1–6). Myelosuppression, in particular neutropenia,
was the most common toxicity (Table 3); grade 3–4 neutropenia
was observed in 16 and 35% of the courses, respectively.
Seven episodes of febrile neutropenia were documented (30% of
the patients) and one patient required hospital admission for
parenteral antibiotic treatment. Patients having febrile neutropenia
or grade 4 neutropenia (at any time in the trial) continued the
treatment with paclitaxel reduced at 155mgm
 2 (72% of the
cycles). No prophylactic GCSFs were administered. Other haema-
tological toxicities were grade 3 thrombocytopenia in 2% and
grade 4 in 1% of the courses; only one episode of grade 4 anaemia
was reported. There were no treatment-related deaths. One patient
received platelets and three patients received blood cell transfu-
sion.
Nonhaematological toxicities were generally mild to moderate:
only one episode of grade 3 diarrhoea was reported; grades 1 and 2
stomatitis occurred in two and three patients, respectively, grade 2
asthenia occurred in five patients and grade 2 vomiting in two
patients. No clinically relevant neurotoxicity, cardiac dysfunction
or hypersensitivity reactions were observed.
Response and survival
In the first step six out of 18 evaluable patients obtained a
complete response: the study proceeded to the second step in
which one additional complete response was achieved (complete
response rate 37% (95% confidence interval (CI)¼16.3–61.4))
According to the statistical design, accrual was stopped at this
point (20 total patients) as we had already obtained the figures we
needed. Nine (47.3%) partial responses were achieved with an
overall response rate of 84.2% ((95% CI¼60.4–96.6)). Three
patients progressed during chemotherapy. One patient was not
evaluable for response (interruption of treatment after the first
course because of arrhythmia). Five out of 20 patients had brain
metastases; after three courses of chemotherapy four patients
obtained an objective response of brain metastases (one patient
obtained a complete response and three patients achieved a partial
response), one patient progressed during chemotherapy.
Median time to progression was 6 months and median overall
survival was 13 months.
DISCUSSION
The treatment of ED-SCLC must be considered as palliative for the
majority of individuals; although chemotherapy is able to achieve
high remission rate and to improve tumour-related symptoms,
very few patients may be cured with standard combination
regimens (overall survival at 5 years is o5%). However, response
to treatment, in particular, complete response, has been suggested
as the major indicator of long-term survival (Paesmans et al,
2000). In ED patients the doublet PE produced complete response
rates ranging from 4 to 23% (Evans et al, 1985; Roth et al, 1992;
Pujol et al, 2001) and the triplets CDE (cyclophosphamide,
doxorubicin and i.v. etoposide) and CAV yielded similar figures
(Ettinger et al, 1990; Roth et al, 1992; Ardizzoni et al, 2002). The
plateau reached by standard treatments stresses the need to test
new drugs and/or new strategies in an attempt to improve the
disappointing clinical results obtained so far.
Among the last generation drugs, paclitaxel is particularly
noteworthy; this drug is highly active in various malignancies and
its documented activity, in refractory patients, makes it especially
interesting for testing in SCLC (Smit et al, 1998). The experience
with paclitaxel, in the treatment of SCLC, is still limited but
promising: available data from literature strongly suggest a high
antitumour activity of paclitaxel-based regimens, with toxicity
profiles which vary according to the different drugs used in
combination. Two recent randomised phase III trials evaluated the
role of this drug in the first-line treatment of SCLC. One trial
compared carboplatin, etoposide and vincristine (standard arm) vs
carboplatin, etoposide and paclitaxel in patients with LD and ED.
The study showed that, on the whole, the risk of death was
significantly higher for patients receiving standard therapy
compared to those allocated to the experimental arm. However,
the significant benefit in survival, provided by the experimental
Table 2 Patients’ characteristics
Phase I Phase II Total
No. patients entered 13 20 33
Median age (years) (range) 65 (61–70) 61 (50–70) 62 (50–70)
Gender
Male 10 18 28
Female 3 2 5
ECOG PS
0 9 12 21
13 6 9
21 2 3
Baseline LVEF (median) 63.3% (57–70%) 58% (50–71%)
Dominant site of disease
Viscera 11 9 20
Soft tissue/bone 2 11 13
Number of metastatic sites
14 3 7
X2 9 17 26
ECOG: Eastern Cooperative Oncology Group; PS: performance status.
Table 3 Grades 3–4 haematological toxicity for all cycles
n¼100
NCI grade %
Cycles 3 4
Neutropenia 15.9 35.2
Thrombocytopenia 2.2 1.1
Anaemia — 1.1
Seven episodes of febrile neutropenia.
Paclitaxel-based regimen in extensive disease SCLC
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sregimen was limited to patients with early stage of disease; no
difference in median survival emerged for ED patients. It is
important to note that this group achieved a higher complete
response rate with the paclitaxel-containing regimen (13.7 vs 7.8%)
(Reck et al, 2003) but the higher activity is probably insufficient to
modify the efficacy results significantly. Consistent achievements
were also reported in the second trial which evaluate the impact of
adding paclitaxel to the standard PE doublet in ED patients. The
triplet required the prophylactic use of G-CSF (Niell et al, 2005).
The study showed a complete response rate of 10% for the doublet
(standard arm) and of 16% for the paclitaxel-based triplet. No
difference in survival emerged between the two arms of this study,
but this could be partially due to the more severe toxicity
(including toxic deaths) reported in experimental treatment;
however, 42% of patients experiencing grade 5 toxicity were older
than 70 years.
In the present study, we tested a new platinum-free triplet
(paclitaxel, epirubicin, etoposide) obtained by substituting cyclo-
phosphamide with paclitaxel in a standard CDE regimen
(cyclophosphamide, epirubicin and etoposide) often used in our
Institution. The phase I study indicated the optimal doses of the
three drugs to be combined and used in the subsequent phase II
study; this was performed in different institutions in order to
verify the applicability of the regimen in everyday practice. The
primary objective of the study was the percentage of complete
response rate considering its potential prognostic significance.
The antitumour activity achieved with our combination was
very high: the overall response rate was 84.2% (95% CI¼60.4
–96.6%) and the 37% (95% CI¼16.3–61.4) complete response
rate was really promising. It is worth noting that these percentages
were obtained in patients with unfavourable prognostic features:
85% of our patients had two or more sites of metastases in addition
to the primary tumour. As expected the most frequent toxic effect
was myelosuppression with grade 3–4 neutropenia recorded in
51% of the courses and seven episodes of febrile neutropenia.
Toxicity data seemed to be comparable with those reported with
standard CDE combination (grades 3–4 neutropenia in 92% of the
patients; febrile neutropenia in 24% of the patients) and slightly
higher than those reported for the PE regimen (grade 3–4
neutropenia ranged between 38 and 66% of the patients; febrile
neutropenia ranged between 6 and 13% of the patients) (Roth et al,
1992; Ardizzoni et al, 2002; Niell et al, 2005). However, it should be
noted that in our study no prophylactic G-CSF was used. As a
matter of fact, in the study by Niell et al (2005), the prophylactic
introduction of G-CSF, in the paclitaxel-containing arm, made the
toxicity profile of the triplet comparable to that of the standard PE.
Other haematological and nonhaematological toxicities, in our
study, were mild to moderate and clinically irrelevant.
In conclusion, our regimen seemed to be feasible and very active
for the treatment of ED-SCLC: the multicentre nature of the
present trial, in which nonspecialised hospitals have also been
involved, and its feasibility in an outpatient setting, make this
regimen worthy of future comparative trials. The introduction of
prophylactic G-CSF could further improve the haematological
toxicity profile of our regimen allowing an easier comparison vs a
standard PE regimen in a large randomised phase III trial.
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